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ABSTRACT 
Mononuclear phagocytes are a widely distributed family of cells contributing to innate and 
adaptive immunity. Circulating monocytes and tissue macrophages participate in all stages of 
SARS COVID-19. They contribute to comorbidities predisposing to clinical infection, virus 
resistance and dissemination, and to host factors that determine disease severity, recovery and 
sequelae. Assays are available to detect viral infection and antibody responses, but no 
adequate tests have been developed to measure the activation level of monocytes and tissue 
macrophages, and the risk of progression to a fatal hyperinflammatory syndrome. Blood 
monocytes provide a window on the systemic immune response, from production to tissue 
recruitment, reflecting the impact of infection on the host. Ready availability of blood makes 
it possible to monitor severity and the risk of potentially lethal complications, by developing 
tests to assess the status of monocyte activation and its potential for further inflammatory 
dysregulation after recruitment to tissues and during recovery. (151 words) 
INTRODUCTION 
COVID-19 infection presents a risk of severe clinical outcome due to a dysregulated 
inflammatory syndrome
1,2
 generated by Mononuclear Phagocytes
3
, a major source of pro-
inflammatory secretion products. Evidence from influenza
4,5
 and previous SARS and MERS
6
 
patients, indicates that blood monocytes respond to tissue encounters in a two-stage 
mechanism of activation
7
, which is not specific to the initiating infection. This is particularly 
relevant in COVID-19 where age and predisposing comorbidities enhance the risk of a severe 
outcome
8,9
. Tests are available to detect infectious virus and anti-viral antibody, but RNA 
alone is not proof of active infection and antibodies may not neutralize, but enhance 
infection
10
. In order to stratify patients at risk of a hyperinflammatory storm and prolonged 
recovery, we developed a novel blood test to assess their level of monocyte activation. It uses 
         
 the canonical CSF1R–CSF1 growth factor receptor11, to characterise all monocytes in blood, 
Figure 1. Further steps include measures of priming during haematopoiesis along myeloid 
differentiation pathways mediated by CSF2R
12
 and CSF3R, and testing their full activation 
potential by selected stimuli, in vitro, as surrogates of activation in tissues. Tests can also be 
used to evaluate macrophage contributions to efficacy of vaccines, anti-viral and anti- 
inflammatory agent trials, to diminish the risk of treatments and facilitate repair. 
Although the airways represent a focus of COVID-19 infection and immediate threat to the 
host, the virus can disseminate systemically and have a profound impact on the body. While 
epithelial and endothelial cells are the major targets of viral infection through expression of 
the ACE2 receptor
13,14
 innate and adaptive immune responses of the host contribute critical 
resistance and pathogenic responses at all stages of disease. Effector cells of the Mononuclear 
Phagocyte System (MPS), whether they become infected
15
 or not, depend mostly on 
recruitment of bone marrow-derived monocytes to tissues 
16-18
 rather than resident 
macrophages of embryonic origin
16,19
. Mononuclear phagocytes collaborate with other 
immune and non-immune pathways to mediate local and systemic anti-viral resistance and 
recovery, while also promoting morbidity and mortality. The MPS is a major contributor to 
the hyperinflammatory and procoagulant secretion syndrome, as demonstrated in earlier 
SARS syndromes as well as COVID-19 infection
20
. Ready access to peripheral blood 
samples from those at risk, provides a window on the dynamics of infection and their 
monocyte activation status, a guide to clinical diagnosis, treatment and prevention. 
2 THE MONONUCLEAR PHAGOCYTE SYSTEM (MPS) 
The MPS is a dispersed organ, present throughout the body, with distinctive properties in 
every organ
21
. Tissue resident macrophage populations in the adult derive from embryonic 
progenitors and differ markedly in phenotype from bone marrow-derived monocytes, which 
are recruited to tissues in response to increased demand, for instance infection and tissue 
damage
19
. Monocyte- derived macrophages are the main generators of inflammation in 
COVID-19
2,17,18,20,22-24
. These mononuclear phagocytes express a broad repertoire of plasma 
membrane and intracellular receptors, serving as sensors of micro-organisms, dying cells and 
soluble products, to mediate recognition, signaling, migration and activation
19
. Monocytes 
and macrophages are professional phagocytes, utilizing Fc, complement, Toll-like and non-
opsonic lectin-like and scavenger receptors for ingestion, but are also highly active 
biosynthetic and secretory cells, contributing to inflammation, innate and adaptive cellular 
and humoral immunity and antimicrobial defences
21
. While promoting tissue homeostasis and 
repair, they also induce tissue injury, the proverbial two-edged sword. They interact readily 
with other cells through contact and soluble mediators including cytokines, chemokines and 
enzymes that activate plasma coagulation and complement cascades
24
; in addition, they 
generate reactive oxygen, nitrogen and arachidonate metabolites implicated in host 
inflammation and resolution
25
. By analogy with lymphocytes, their activation status is 
characterized for convenience as M1-type (pro-inflammatory) and M2-type (anti-
inflammatory, reparative)
7
. Unlike T and B lymphocytes, mononuclear phagocytes are 
antigen non-specific, and only display a transient form of memory
26
, primed to adapt to 
         
 secondary challenges such as phagocytosis and microbial stimuli by further activation of 
potent secretory and cytotoxic pathways
7
. The level of activation covers a spectrum of 
effector mechanisms, constrained by inhibitory cytokines such as IL-10, IL-1 receptor 
antagonist
27
 and transforming growth factor beta TGF-β, and by anti-inflammatory 
glucocorticoids and prostaglandins. 
3 COVID-19 INFECTION  
3.1 It is customary to divide the course of the infection into different stages: Preinfection (co-
morbidities), asymptomatic, early clinical, severe clinical (acute respiratory distress 
syndrome–ARDS), and recovery8,9, Figure 2. This natural timing should be used to establish 
key point-of-care sampling timepoints, avoiding patient discomfort and to focus resources. 
Infection can progress or be aborted at every stage, presenting a dynamic continuum, to 
which macrophages and monocytes contribute, together with other immune and non-immune 
elements; MPS contributions to COVID-19 resistance and pathogenesis are still 
underestimated and poorly understood. 
3.2 CO-MORBIDITIES AND THE MPS 
Macrophage activities contribute to many co- morbidities
8,9
, including aging
28
, obesity
29
, 
diabetes
30
, exposure to pollutants
31
, and microbiome properties
32
. Macrophage functions alter 
with age, together with adaptive immune processes such as thymic involution, which deplete 
T lymphocyte reserves. Chronic, low grade inflammation (INFLAMMAGING) has been 
proposed as a predisposing factor
33
. This may result from failure of macrophages and NK 
cells to clear increasing accumulation of senescent cells, that enhance basal levels of 
inflammation and interfere with subsequent adaptive immunity upon infection
28
. Baseline 
inflammation may not be detrimental in itself, but can initiate an inflammatory cascade that 
amplifies excessive inflammation occurring in response to pathogens. Age-related metabolic 
correlates of macrophage dysfunction include innate lymphoid cell interactions with adipose 
tissue and associated macrophages, as well as inflammasome activation
34,35
. This affects 
thermogenesis, part of a wider metabolic syndrome involving glucose and lipid metabolism
36
, 
elevated body mass index (BMI), type 1 and type 2 diabetes, obesity and atherosclerosis
37
. 
These correlate with macrophage metabolic and mitochondrial activities
38
 and, possibly, 
ACE2 expression and hypertension, another co-morbidity
37
. ACE2, the COVID-19 entry 
receptor, is widely expressed on microvascular endothelium and binds the SARS-CoV2 spike 
glycoprotein implicated in angiotensin regulation by its competition with ACE1, and 
potential role as an anti-inflammatory agent
39
. Macrophages in tuberculosis and sarcoidosis 
express ACE1
40
, but expression of ACE2 by monocytes and tissue macrophages has not been 
validated
41
; evidence for productive infection of macrophages via ACE2 is incomplete
15
. 
Macrophages express scavenger receptors including Axl and MERTK, tyrosine kinase 
receptors implicated in phosphatidyl serine recognition and phagocytosis of apoptotic cells
21
; 
Axl is a coreceptor for ACE2+ dependent infection of other cell types by COVID-19 and 
other enveloped viruses via surface or endocytic routes
42
, the basis for a clinical trial 
involving an Axl inhibitor. 
         
 Alveolar macrophages
43
 are close to Type 1 pneumocytes, involved in gas exchange, Type 2 
surfactant-producing pneumocytes, and capillary endothelium, all ACE 2+
43
. They take up 
and store atmospheric pollutants and poorly-degradable pro-inflammatory particles; host 
DNA from dying cells can induce the innate STING pathway after uptake and also activate 
inflammasomes in lung macrophages after exposure to ozone and cigarette smoke
31
. Other 
airway predisposing conditions involving macrophages
8,9
, include genetic disorders such as 
fibrocystic disease and structural abnormalities associated with chronic inflammation and 
infection. 
Chronic infections in which TH1-activated macrophages play a major role, tuberculosis and 
AIDS, enhance the risk of severe infection, with odds ratios of 1.7 and 2.3– respectively. 
TH2-dependent asthma may not enhance COVID-19 susceptibility, possibly correlated with 
low levels of ACE2 expression
44
. IL-13 also reduces ACE2 expression, suggesting that M2-
macrophages may contribute to viral resistance. BCG and other immunisations may 
transiently promote non-specific resistance to SARS-CoV2
45
, to be confirmed in trials. 
Mononuclear phagocytes are implicated in selected genetic
46
 or acquired systemic 
immunodeficiency, immunosuppression and autoimmunity, including chronic renal disease 
requiring organ transplantation. Tumour associated macrophages (TAM) and Myeloid 
derived suppressor cells (MDSC) promote malignancy and metastasis, and with chemo-and 
radiotherapy may enhance COVID-19 risk. Microglia contribute to neurodegeneration 
through interaction with neurons in Alzheimer disease, a comorbidity independent of age. 
Comorbidities are likely to be multifactorial, and not all display an obvious macrophage link; 
for example, the ACE2 locus on the X chromosome
47
 may contribute to the decreased risk of 
females
48
, but genetic and environmental factors underlying gender, racial and individual 
disparities remain unclear. Therapeutics for many comorbidities impact on macrophage 
inflammatory and metabolic functions, including statins, sugar stabilizers, anti-hypertensives 
and anti-inflammatory agents; control of diabetes and obesity are important in preventing 
severe infection. Glucocorticoids, which have potent anti-inflammatory effects on 
macrophages, are contra-indicated in early infection, while protecting against severe disease; 
timing of administration is therefore critical
49
. The use of anti-TNF antibody in treatment of 
rheumatoid arthritis, protects against subsequent severe COVID-19 requiring 
hospitalization
50
. 
In conclusion, the present evidence for a common macrophage contribution to a range of 
comorbidities is correlative, rather than causal. Nor is it clear whether they increase the risk 
as well as the severity of infection. Macrophages are central to inflammation, immunity and 
metabolic diseases, but further genetic and cellular studies are needed to provide a unifying 
hypothesis. 
3.3 ASYMPTOMATIC AND INITIAL, MILD INFECTION 
There is little direct evidence how monocytes and tissue macrophages contribute to 
asymptomatic infection, but their tissue distribution, receptor repertoire and secretory 
capacity are vital to viral resistance as well as dissemination. Acute macrophage antiviral and 
inflammatory responses determine the outcome of infection, together with other innate and 
         
 adaptive host mechanisms. We outline evidence from clinical
20
 and experimental 
observations from earlier
51
 and current
20
 coronavirus studies and consider the role of 
macrophages and monocytes in local and systemic infections, the antiviral and inflammatory 
response, resolution and complications. 
Most COVID-19 infections follow droplet inhalation and upper respiratory airway infection, 
which can be asymptomatic or mild, depending on mucosal immunity and IgA protection. 
Nasopharyngeal epithelium expresses ACE2 and is an early target for infection. Even if local 
tissue macrophages do not express ACE2 receptors and are not directly infected, they play a 
role in inflammatory cytokine responses to infected cells through surface, endosomal and 
cytosolic receptors and secretion of IL-1 family members
52
 and antiviral interferons (IFNs). 
Monocytes, dendritic cells and tissue macrophages can bind virus through lectin-like 
receptors such as CD169
53
, for transport to regional lymph nodes. Delivery of virus droplets 
to the lower respiratory tract leads to infection of ACE2+ alveolar epithelium and capillary 
endothelium. Detection of intracellular RNA in alveolar macrophages could result from 
uptake of infected epithelial and endothelial cell debris rather than active infection. Single 
cell mRNA studies of bronchoalveolar lavage in COVID-19, have confirmed the recruitment 
of inflammatory monocytes as well as the presence of reactive alveolar macrophages in 
lung
17,18
. 
Several common symptoms of early infection can be the indirect result of epithelial cell 
necrosis by viral infection mediated by ACE2 and/or other co-receptors, such as 
transmembrane protease serine 2, (TMPRSS2)
13
. Uptake of virus or epithelial cell debris by 
lung macrophages can initiate inflammasome activation by P2RX7 and release IL-1β, Type1 
IFN, IL-6 and TNF
3
, contributing to fever, pain, lethargy and headache. Raised levels of C-
reactive protein (CRP), induced in hepatocytes by IL-6, are acute phase, plasma biomarkers 
of COVID-19. Other macrophage products include chemokines such as IL-8 (CXCL8) and 
MCP-1 (CCL2), recruiting abundant PMN and monocytes to sites of infection. Through 
viraemia COVID-19 reaches systemic organs such as heart, gut, brain and kidney, which 
contain resident and recruited macrophage populations; these contribute to local, specialised 
dysfunctions, such as myocarditis and cardiac arrhythmia, following interactions of 
macrophages and infected cardiomyocytes
54
. Intravascular coagulation
3,24
 promotes 
dissemination of microthrombi-emboli to lungs, heart and brain, and fibrin degradation D-
dimers appear in blood. This is evidence of early resolution, enhanced by the generation of 
antiviral IgM and IgG. 
We have little understanding of the innate and adaptive mechanisms that fail to clear local 
viral infection and at what stage IFN
55,56
, other pro-inflammatory
57
 and haematopoietic 
responses become dysregulated in blood monocytes
58
. Together with compromised lung 
oxygenation, this can lead to systemic immune and vascular dysfunctions. A syndrome of 
mild infection in younger subjects gives rise to chilblain-like inflammation in toes and 
fingers
59
. The uncommon multisystem Kawasaki-like inflammatory syndrome of children 
results from atypical immune responses to COVID-19
60,61
. This involves anti-viral antibody, 
systemic vasculitis affecting heart rather than lung, and can respond to corticosteroids. Apart 
from platelet activation, mononuclear phagocytes are known to produce tissue factor and 
         
 other procoagulants
62
, factors and 13; fibrinolysis by vascular endothelium and inflammatory 
macrophages
63
 is mediated by secretion of urokinase, which cleaves plasminogen to plasmin; 
its activity is regulated by inhibitors in plasma, such as alpha2 macroglobulin. Anticoagulants 
and intranasal or inhaled Type1 IFN may be useful inhibitors of thrombosis and local viral 
infection, limiting progression to more severe infection. 
3.4 MODERATE AND SEVERE INFECTION: THE HYPERINFLAMMATORY 
SYNDROME 
Between 8-12 days after COVID-19 infection, patients can progress to severe lung infection 
characterized by pneumonia, increased vascular permeability, oedema, and hypoxia, 
requiring oxygen or mechanical ventilation. This is part of a systemic viral infection of 
ACE2+epithelia and endothelia, widespread cell death, ischaemia, hypotension and organ 
failure. Blood analysis at time of hospitalization, has revealed polymorphonuclear 
leukocytosis, reduced levels of abnormal monocytes and lymphopaenia
58,64
. Myeloid cell 
recruitment to lung contributes to the hyperinflammatory and coagulopathy acute respiratory 
distress syndrome (ARDS)
20
. This is accompanied by monocyte/macrophage dysregulated 
production of secretory products. It is not clear which factors contribute to this complication: 
enhanced viral growth–perhaps triggered by early, poorly neutralizing IgM and complement 
or IgG, hypoxia and loss of antiviral mechanisms of macrophages–directly or secondary to 
lymphopaenia, massive local epithelial and endothelial necrosis, hyperactivation of newly 
recruited immature monocytes, or a “perfect storm” encompassing several of the above. This 
syndrome could be triggered by induction of ACE2 on specific populations of monocytes and 
macrophages, resulting in their direct infection. By this stage, spleen and draining nodes at 
sites of infection are severely disorganized
65
. M1-like monocytes carrying virus through 
CD169 or other receptors, whether infected or not, can disseminate the virus throughout the 
body by a Trojan horse mechanism
66
. It is not known whether lymphocytes, not infected, die 
by apoptosis or necrosis, from products of activated lymphocytes or macrophages such as 
TNF, or by phagoptosis. We summarise evidence that blood monocytes and activated tissue 
macrophages contribute to severe COVID-19 and consider virus-induced macrophage 
pathogenetic mechanisms, which can be targeted therapeutically. 
Earlier studies on SARS1/MERS revealed many of the features of ARDS and of macrophage 
involvement
6,51
. Initial blood and tissue analysis of COVID-19 provided morphologic 
evidence of monocyte abnormality and intense macrophage phagocytic activity in infected 
organs
65
. FACS and single cell RNA analysis of monocytes and broncho-alveolar 
macrophages
18
 provided evidence of emergency myelopoiesis
64
 and confirmed the presence 
of recruited and activated macrophages in alveoli
17
 and lung interstitium. Plasma membrane 
opsonic and other receptors contribute to dysregulated inflammation, monocytic 
hyperactivation and impaired phagocytic clearance of apoptotic and necrotic cells and debris. 
Acting through NFkB, RNA, DNA and other sensing and signaling pathways, they initiate 
production of numerous secretory products. Particular antiviral and proinflammatory products 
have been targeted for anti-inflammatory treatment, including the IFNs
55,56
, IL-1 family
52
, IL-
6
27
 and TNF
22
. In addition, mononuclear phagocytes interact with plasma cascades, and 
         
 through upregulated adhesion molecules, with other myeloid and lymphoid cells, platelets, 
system-wide endothelia and epithelia. 
Dysregulated activation of macrophages contributes to the hyperinflammatory and 
thrombotic pathways of severe COVID-19
3,24,67
.Virus-induced cell injury, apoptosis, necrosis 
and necroptosis are sensed by distinct, opposing macrophage receptor-dependent effector 
responses. These include activating and inhibitory pathways of IL-1 production, processing 
and secretion
52,57
, triggered by tissue injury, inflammasome and caspase activation. A highly 
impaired type1 IFN response, characterized by no IFN and low IFN production and 
activity, has been associated with persistent viraemia and an exacerbated inflammatory 
response, partially driven by NFkB, TNF and IL-6
56
. Endogenous oxidized phospholipids 
reprogramme macrophage metabolism and boost hyperinflammation
68
. By capturing 
inflammatory lipids released from dying cells, CD14 induces inflammasome-dependent 
phagocyte hyperactivation
69
. Macrophage fuel production and utilization
36
 are sensitive to 
hypoxia, HIF-1 responses
70
 and iron availability, influencing M1 polarization and effector 
functions. Activated macrophages trigger coagulation and complement cascades, as well as 
angiotensin and bradykinin pathways that dysregulate vascular tone and permeability, 
exacerbating inflammation and oedema. 
Immunological processes that may contribute to the outcome of macrophage- viral induced 
pathology include antibody enhancement of infection (ADE) and inflammation (ADI), and 
neutrophil NETosis. Anti-spike antiserum can induce hyperinflammation via macrophage 
FcR, depending on IgG glycosylation and Syk involvement
71
. Cross-reacting antibodies from 
previous benign coronavirus infections also contribute to enhanced pathology
72
. Dendritic 
cell dysfunction, ascribed to down regulated HLA-DR expression
67,72
 and defective antigen 
presentation to T and B lymphocytes, may result from lack of costimulatory signals, aborting 
lymphocyte proliferation and activation and mediating widespread clonal death. 
Haemophagocytosis, a feature of the macrophage activation syndrome (MAS), is also 
observed in other viral infections. 
3.5 RECOVERY 
Macrophages are central to the cellular processes which contribute to recovery from COVID-
19 infection; they remove debris and necrotic tissue through phagocytosis and secretion of 
elastase and collagenase, and produce IGF1 and TGF-β to promote tissue recovery. M2-like 
macrophages are the source of potent lipid metabolites which resolve inflammation; these 
include resolvins, protectins and maresins, short lived autacoids which regulate the 
magnitude and duration of acute inflammation
25,73
. Acting through macrophage GPCRs for 
these metabolites, they enhance efferocytosis of dying neutrophils, and counter inflammation 
without immunosuppression. 
Recovery can be prolonged after severe infection, involving fever, lethargy, scarring and loss 
of organ function. Italiani and colleagues profiled the course of resolving versus persistent 
inflammation with special reference to IL-1 family molecules
57
. An independent single cell 
mRNA analysis of peripheral blood mononuclear cells during early recovery of COVID-19 
infection
23
, revealed an increased ratio and level of classical CD14
++
IL-1+ monocytes. 
         
 Further studies are needed to compare monocytes and tissue macrophages after mild or 
severe infection and to establish whether repolarisation of macrophages from M1 to an M2 
phenotype can promote resolution and recovery after COVID-19. After helminth infection, 
M2 macrophages express resistin, which protects against LPS-induced toxic shock
74
. New or 
repurposed therapies may be able to modify the sequelae of severe infection. 
 
4 MONOCYTE ACTIVATION ASSAY: RATIONALE 
Blood monocytes provide a window on mononuclear phagocyte production, distribution and 
activation in the healthy and infected body. The level of circulating monocytes depends on 
circadian release from bone marrow, adhesion to endothelial surfaces and tissue entry. Blood 
from hospitalized patients has shown a decrease in the proportion of monocytes, increased 
size, low CD14, high CD169 and low HLA-DR, consistent with release of immature, more 
replicating Ki67+ monocytes from the bone marrow during emergency haematopoiesis
64
. 
Monocytes respond through specific plasma membrane receptors to CSF1, CSF2 and CSF3 
during differentiation, and to IFNs, pro- and anti-inflammatory cytokines, during immune 
activation. In the steady state, monocytes circulate with a half-life of 1-2 days; turnover is 
enhanced after LPS
75
 and severe influenza infection, which induces morphologic changes and 
a pro-inflammatory M1-like activation phenotype
4
, similar to changes in COVID-19
64
. This 
provides a rationale for use of monocyte gene expression and antigen markers, combined 
with in vitro exposure to phagocytic and TLR stimuli, to assess maximal pro-inflammatory 
M1 activation. The levels of TNF and other proinflammatory cytokines observed in vivo 
during COVID-19 may be lower than after bacterial sepsis. It is therefore essential to extend 
analysis to a broad range of secretory products. 
4.1 CONSIDERATIONS 
The balance of pro- versus anti-inflammatory activation determines the protective versus 
deleterious impact on the host. In vivo priming, combined with innate and adaptive immune 
triggers in vitro, provide a surrogate assay for potential activation of monocyte-derived 
macrophages in tissues, Figure 1. The number of monocytes and their activation status can be 
assayed by combining analysis of CSF1-, CSF2- and CSF3- receptors during growth and 
differentiation, with markers of M1/M2-like activation; gene expression biomarkers are 
available at different stages of COVID-19 infection for each pathway, and in response to a 
range of activating and deactivating stimuli. Figure 2 illustrates testing points in the natural 
history of COVID-19 infection and lists requirements for a comprehensive monocyte 
activation assay. This provides insights into the contribution of monocytes to pathogenesis, 
and guides treatment. Monocyte tests can be combined with viral and antibody tests at any 
stage of infection, providing access to an intermediate stage between haematopoiesis and 
tissue effector functions. Regulators of monocyte activation which can be tested in vitro 
include innate and adaptive immune cells, viral proteins, antiviral agents and anti-
macrophage therapeutics. 
Reconstitution of lymphopaenia may contribute to a viral-induced storm resembling the 
Immune Reconstitution Inflammatory Syndrome (IRIS) observed in tuberculosis patients 
         
 with AIDS as lymphocyte counts recover during anti-retroviral treatment
76
. The phenomenon 
of antibody-dependent enhancement (ADE) of flavivirus infections
10
, has not been 
demonstrated for COVID-19, to date. However, anti COVID-19 antibodies and immune 
complexes, induced by prior vaccination, during the course of the disease or by passive 
transfer of IVIg or pools of “elite” mab5,71, may enhance dysregulated inflammatory 
responses of primed monocytes through Fc- and complement receptors. This entails 
characterization of ITAM/ITIM monocyte FcR functions, analysis of reactive oxygen and 
nitrogen metabolites, cytokine secretion, procoagulant and fibrinolytic responses, and cellular 
cytotoxicity. Longitudinal studies of monocyte activation and cost/benefit analysis of any 
immune interventions are therefore mandatory. 
5 PERSPECTIVE 
What distinguishes SARS-CoV2 from other viruses, including other coronaviruses, although 
the hyperinflammatory storm is clearly a feature of its forerunners
6
. A strong candidate must 
be the expression level of ACE2 as a viral entry receptor. The host also determines the 
outcome of exposure to the virus. In his prescient views of the role of the external and 
internal host environment, Rene Dubos differed from the standard germ theory of infectious 
disease, as necessary, but not sufficient
77
. The pre- and post- clinical features of the present 
pandemic illustrate this concept superbly. Although host susceptibility and severity of 
infection are clearly multifactorial, there is a thread from the role of its receptor in 
angiotensin regulation, vascular tone and permeability, through hypertension and 
cardiovascular function. The connection with the metabolic syndrome suggests an unknown 
link to lipid metabolism, including interactions of adipocytes and macrophages 
35
. 
Separate streams of the mononuclear phagocyte lineage co-exist to generate monocytic, 
granulocytic and dendritic cell-like monocytes
78
, and the impact of COVID-19 infection on 
monocyte activation needs to be determined to identify targets for diagnosis and intervention. 
The different monocytic lineage receptors for CSF1, 2 and 3 provide direct markers of 
disturbed haematopoiesis and skewed cell differentiation
79
; and can be combined with 
downstream effectors such as CD14
80
 and FcR to determine their full activation potential. 
Anti-growth factor/cytokine receptor antibodies may therefore be more effective in 
attenuating a hyperinflammatory storm and attendant organ damage than using individual 
anti-cytokine reagents for GM-CSF, IL-6 and TNF, for example
22
. Recent studies with anti 
CSF2R blockade by mavrilimumab show promise
12,81
 and anti CSF1R blockade presents an 
alternative or additional option. Repurposing trials of anti-inflammatory drugs have targeted a 
variety of macrophage pathways, with mixed results. In each case, we have to weigh potential 
benefits against interfering with macrophage antimicrobial and other essential functions such 
as antiviral-antibody dependent killing, clearance of necrotic cells and debris, and repair, as 
well as the risk of potentiating inflammatory responses of mononuclear phagocytes through 
antibody -dependent mechanisms. 
Macrophage “activation” is a complex process with limited knowledge of its regulation or 
variable expression in different tissues and by diverse causes
7
. Reciprocal interactions 
between mononuclear phagocytes and adaptive T and B lymphocyte subtypes play a decisive 
         
 role in the control of macrophage activation. Further studies on monocytes from infected 
patients will establish how this virus manipulates innate and adaptive control mechanisms to 
facilitate its survival and spread. 
6 OUTSTANDING QUESTIONS 
1. Define the molecular basis for mononuclear phagocyte contributions to different 
stages of COVID-19 resistance and pathogenesis. 
2. Define interactions between mononuclear phagocytes, COVID-19 and other host cells 
in different tissues. 
3. Develop tests to quantify biomarkers of monocytes and tissue macrophages during 
COVID-19, for diagnosis, prognosis, therapy and prevention. 
 
Figure Legends. 
 
Figure 1 
 
Figure 1. Monocytes represent a window between bone marrow and tissues. Blood 
monocytes are circulating intermediates between haematopoiesis in bone marrow and 
recruitment to tissues in response to turnover of resident macrophages of embryonic origin, 
and to increased demands following tissue inflammation, infection and malignancy. The 
CSF1 Receptor is a pan-monocyte marker expressed by all subsets of monocytes defined by 
CD14, CD16 and DCs lacking both of these antigen markers. Together with CSF2R and 
CSF3R, these three lineage differentiation markers enable identification of distinct streams of 
monocytic, granulocytic and Dendritic cell types of monocyte differentiation. In response to 
the prototypic TH1 or TH2 cytokines, IFN and Interleukin 4/13, monocytes are polarized to 
distinct M1-like, classically activated, and M2-like, alternatively activated macrophages. 
         
 Each becomes fully activated by further local phagocytic stimulation by microbes and 
apoptotic cells, respectively. CD40 and CD64 are M1-like markers, where CD40 is for 
detecting TLR4 pathway and CD64 is for detecting IFN activation, while CD200R is an M2-
like marker. Other markers can be introduced as required. 
 
 
Figure 2 
Figure 2. Decision points that determine the outcome of COVID-19 infection and 
requirements for a monocyte activation assay. A time and severity pattern has emerged for 
Co-morbiditiesHealthy 
Pre-infection 
Asymptomatic Severe clinical 
(ARDS) 
Mild clinical
Recovery Death
COVID-19
Blood monocytes provide a window on mononuclear phagocytic production,
distribution and activation in the healthy and infected body.
1-A monocyte test must be able to quantify these cells with precision in blood at
selected time points.
2-The test must include markers of inflammation and healing, or M1 and M2. This
can be at any level accessible from mRNA to lipids.
3-Biomarkers for stratification at a clinical level should guide cohort selection to
detect patients at high risk of hyperinflammation.
4-Ageing and comorbidity effects in circulating monocytes need including, specially
viral receptor expression.
5-The test should include indications of macrophage secretion products, pro-
coagulation and fibrinolysis, and in vitro readouts of maximal activation by tissue
inflammatory signals.
6-Receptors which mediate the crosstalk of macrophages with innate and adaptive B
and T immune cells, e.g. FcR and C3bi, which will guide vaccine safety.
7-Deactivation induced by apoptosis of inflammatory cells and resolvins should also
be tested.
8-Examine Interactions with healthy and infected endothelial and epithelial cells.
9-Monitor recovery and sequelae in systemic organs, considering fibrosis, scarring
and persistent inflammation.
10-Identify candidate genes which mediate resistance or susceptibility to the virus.
Day 0-3
Week 1 
Week 2 
         
 COVID-19 progression. The first days, first and second week timelines are turning points for 
resolution or deterioration. Epidemiologic precision for these milestones and precise 
parameters will be valuable for strategic sampling and patient stratification, sparing resources 
and patient material. With limited volumes of peripheral blood, a window on progression of 
the infection can be obtained by studying activation of the mononuclear phagocyte system, 
largely represented by monocytes in blood. The cells are biosynthetically active and 
relatively long lived, ideal to trace long term effects of comorbidities and infection. We 
highlight selected functional categories that should be addressed in monocytes and can be 
adapted to particular applications. 
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syndrome corona virus; MERTK, MER proto-oncogene tyrosine kinase; MCP-1, 
Macrophage chemotactic protein 1; NETosis Neutrophil extracellular trap; MPS, 
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 Search strategy and selection criteria 
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